Pharmaceutical Industry
Pharmaceutical Industry
Two Bets on Complex Molecules, One Asset Light Model
HRV Pharma is planning a ₹150 crore investment in peptides and high-potency APIs through a dedicated peptide programme and a joint venture focused on specialised oncology molecules. Both initiatives follow the company's asset-light model, retaining intellectual property, regulatory assets and commercial rights while working with specialist manufacturing partners.
From Manufacturing Scale to Institutional Intelligence
The pharmaceutical industry's competitive edge is evolving from manufacturing capacity to institutional intelligence. Indian Pharma Post explores how HRV Pharma's RIKO uses seven years of proprietary operational data to assess risks, accelerate supplier qualification and support smarter pharmaceutical decision-making.
The Question That Built RIKO
Why do preventable pharmaceutical problems keep recurring years after key decisions are made? Digital Health News explores how HRV Pharma's RIKO uses seven years of operational workflows and ten federated reasoning models to identify risks earlier, accelerate supplier qualification and support faster pharmaceutical decision-making.
One System for Both Sides of Pharma
HRV Pharma's RIKO is designed to bridge the gap between pharmaceutical manufacturers and customers. Drawing on millions of proprietary decisions across 55 countries, the AI-native platform supports faster partner qualification, transparent enquiry matching and early risk assessment across the pharmaceutical value chain.
Catching Risk Before It Becomes a Recall
In the pharmaceutical industry, identifying risks early can help prevent costly quality failures and recalls. PharmaClick explores how HRV Pharma's RIKO platform uses AI-driven pharmaceutical intelligence to assess chemistry risks, nitrosamine potential, supplier reliability and regulatory history before commitments are made.
RIKO by the Numbers
Millennium Newsroom highlights the reported results of RIKO, HRV Pharma's AI-native pharmaceutical operating system. From 94% predictive accuracy in early nitrosamine risk assessments to 85% faster supplier qualification and commercial enquiry screening in under two seconds, RIKO applies pharmaceutical decision intelligence to real business challenges.
Meet RIKO, Built From Seven Years of Pharma Decisions
HRV Pharma has launched RIKO, an AI-native pharmaceutical operating system built on more than seven years of industry decisions. Drawing on insights from a network of 50+ FDA and EU GMP certified partners and customers across 55 countries, RIKO brings together AI-driven reasoning to support pharmaceutical sourcing, risk assessment and supplier qualification.
Trust Isn't a Feeling. It's a System.
How can a pharmaceutical company maintain quality without owning its manufacturing plants? HRV Pharma builds trust through standardised audits, real-time performance tracking and continuous visibility across 53 partners, helping identify issues before they become shipment or regulatory problems.
Not a Capacity Problem, a Utilisation Problem
When Hari Kiran Chereddi founded HRV Pharma in 2016, he saw an opportunity to address underutilised pharmaceutical manufacturing capacity in India. In this ET Now interview, he explains HRV's asset-light model, its quality assurance systems across 53 sites, and its ambition to reach ₹1,000 crore while remaining debt free.
What Indian Pharma Is Really Buying
Sun Pharma's $11.75 billion acquisition of Organon highlights a broader shift in the Indian pharmaceutical industry. Featuring insights from industry leaders, including HRV Pharma's Hari Kiran Chereddi, BioSpectrum explores the growing importance of brand value, specialty portfolios, biosimilars and access to regulated global markets.
No Factory, ₹400 Crore Revenue: How HRV Made It Happen
How does HRV Pharma generate over ₹400 crore in revenue without owning a manufacturing plant? Discover its asset-light business model, network of 50+ US FDA and EU approved manufacturing partners, and growth to 700+ customers across 55 countries.